Larimar Therapeutics Inc (LRMR)

$2.81 -0.16 (-5.39%)
Market Cap 245.85M
Revenue (ttm) 0.00
Net Income (ttm) -80.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 907,700
Avg Vol 1,117,038
Day's Range N/A - N/A
Shares Out 82.78M
Stochastic %K 12%
Beta 1.00
Analysts Strong Sell
Price Target $14.67

Company Profile

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Industry: Biotechnology
Sector: Healthcare
Phone: 844 511 9056
Address:
Three Bala Plaza East, Suite 506, Bala Cynwyd, United States
alexpitti
alexpitti Feb. 24 at 5:30 AM
$LRMR I believe management will announce the talks with the FDA went well and the bla filing will go on with no delay in q2
0 · Reply
mmtiddy
mmtiddy Feb. 23 at 6:51 PM
$LRMR Falling off a cliff
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 6:45 PM
$LRMR Current Stock Price: $2.80 Contracts to trade: $2.5 LRMR Mar 20 2026 Call Entry: $0.45 Exit: $0.64 ROI: 42% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 12:33 PM
$LRMR RSI: 31.61, MACD: -0.1283 Vol: 0.24, MA20: 3.35, MA50: 3.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillyHouse264
BillyHouse264 Feb. 21 at 6:21 AM
$LRMR Larimar Therapeutics develops rare disease treatments. Clinical milestones drive valuation. Early-stage biotech risk is high.
0 · Reply
Mhlandlord
Mhlandlord Feb. 20 at 1:46 PM
$LRMR Something is going on. Anybody got a clue?
1 · Reply
Mhlandlord
Mhlandlord Feb. 19 at 9:15 PM
$LRMR Why the uptick late?
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 19 at 2:54 PM
$LRMR trading like no dice on Q1 filing
1 · Reply
NocturneTrades
NocturneTrades Feb. 18 at 7:09 AM
$LRMR Laramide Resources is a uranium development company, leveraged to uranium spot price with long lead times to production [citation:historical].
1 · Reply
kenny91655
kenny91655 Feb. 17 at 3:03 PM
$LRMR Buying
0 · Reply
Latest News on LRMR
Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Jan 16, 2026, 6:17 AM EST - 5 weeks ago

Larimar Therapeutics: The Market Is Mispricing A Potential Standard Of Care

Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 2:36 PM EST - 5 weeks ago

Larimar Therapeutics, Inc. (LRMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 18, 2025, 8:00 AM EST - 2 months ago

Larimar Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Top 3 Health Care Stocks That May Rocket Higher In December

Dec 3, 2025, 6:45 AM EST - 2 months ago

Top 3 Health Care Stocks That May Rocket Higher In December

ORIC PRGO

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 7:00 AM EST - 3 months ago

Larimar Therapeutics Reports Third Quarter 2025 Financial Results

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

Oct 16, 2025, 4:44 AM EDT - 4 months ago

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - LRMR

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Oct 16, 2025, 4:40 AM EDT - 4 months ago

LRMR Investors Have Opportunity to Join Larimar Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

Oct 15, 2025, 9:30 PM EDT - 4 months ago

Larimar Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – LRMR

Larimar Therapeutics, Inc. - Special Call

Sep 29, 2025, 2:47 PM EDT - 5 months ago

Larimar Therapeutics, Inc. - Special Call

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Sep 29, 2025, 11:20 AM EDT - 5 months ago

Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

Sep 29, 2025, 7:00 AM EDT - 5 months ago

Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich's Ataxia

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Sep 28, 2025, 5:00 PM EDT - 5 months ago

Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 7:00 AM EDT - 6 months ago

Larimar Therapeutics Reports Second Quarter 2025 Financial Results

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Jul 31, 2025, 4:15 PM EDT - 7 months ago

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Jul 29, 2025, 11:50 PM EDT - 7 months ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Jul 29, 2025, 4:01 PM EDT - 7 months ago

Larimar Therapeutics Announces Proposed Underwritten Public Offering

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Jul 8, 2025, 7:00 AM EDT - 8 months ago

Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Jun 23, 2025, 7:00 AM EDT - 8 months ago

Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Jun 20, 2025, 4:05 PM EDT - 8 months ago

Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Apr 30, 2025, 7:00 AM EDT - 10 months ago

Larimar Therapeutics Reports First Quarter 2025 Financial Results

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 24, 2025, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Mar 3, 2025, 4:05 PM EST - 1 year ago

Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Jan 23, 2025, 4:05 PM EST - 1 year ago

Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

Jan 3, 2025, 5:49 PM EST - 1 year ago

Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better

What's Going On With Larimar Therapeutics Stock On Tuesday?

Dec 17, 2024, 1:39 PM EST - 1 year ago

What's Going On With Larimar Therapeutics Stock On Tuesday?

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Dec 16, 2024, 12:17 PM EST - 1 year ago

Why Is Larimar Therapeutics Stock Trading Lower On Monday?

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Dec 16, 2024, 7:00 AM EST - 1 year ago

Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 30, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oct 16, 2024, 2:59 PM EDT - 1 year ago

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 6, 2024, 9:28 PM EDT - 1 year ago

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Sep 19, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31, 2024, 4:11 PM EDT - 1 year ago

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

May 30, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

May 20, 2024, 4:05 PM EDT - 1 year ago

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 9, 2024, 7:00 AM EDT - 1 year ago

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Mar 14, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Mar 11, 2024, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Mar 6, 2024, 4:05 PM EST - 2 years ago

Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Feb 14, 2024, 6:15 AM EST - 2 years ago

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Feb 12, 2024, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Nov 14, 2023, 7:00 AM EST - 2 years ago

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Nov 1, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Oct 3, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Aug 31, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Larimar: Friedreich's Ataxia Drug With Significant Potential

Aug 2, 2023, 6:02 AM EDT - 2 years ago

Larimar: Friedreich's Ataxia Drug With Significant Potential

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Jul 25, 2023, 7:00 AM EDT - 2 years ago

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial and to Initiate Open Label Extension Trial

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Jul 17, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

Larimar Therapeutics Set to Join Russell 3000® Index

Jun 21, 2023, 4:05 PM EDT - 2 years ago

Larimar Therapeutics Set to Join Russell 3000® Index

alexpitti
alexpitti Feb. 24 at 5:30 AM
$LRMR I believe management will announce the talks with the FDA went well and the bla filing will go on with no delay in q2
0 · Reply
mmtiddy
mmtiddy Feb. 23 at 6:51 PM
$LRMR Falling off a cliff
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 23 at 6:45 PM
$LRMR Current Stock Price: $2.80 Contracts to trade: $2.5 LRMR Mar 20 2026 Call Entry: $0.45 Exit: $0.64 ROI: 42% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Feb. 21 at 12:33 PM
$LRMR RSI: 31.61, MACD: -0.1283 Vol: 0.24, MA20: 3.35, MA50: 3.51 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillyHouse264
BillyHouse264 Feb. 21 at 6:21 AM
$LRMR Larimar Therapeutics develops rare disease treatments. Clinical milestones drive valuation. Early-stage biotech risk is high.
0 · Reply
Mhlandlord
Mhlandlord Feb. 20 at 1:46 PM
$LRMR Something is going on. Anybody got a clue?
1 · Reply
Mhlandlord
Mhlandlord Feb. 19 at 9:15 PM
$LRMR Why the uptick late?
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 19 at 2:54 PM
$LRMR trading like no dice on Q1 filing
1 · Reply
NocturneTrades
NocturneTrades Feb. 18 at 7:09 AM
$LRMR Laramide Resources is a uranium development company, leveraged to uranium spot price with long lead times to production [citation:historical].
1 · Reply
kenny91655
kenny91655 Feb. 17 at 3:03 PM
$LRMR Buying
0 · Reply
LisaShiroma238
LisaShiroma238 Feb. 11 at 2:31 PM
$LRMR Laramide Resources; uranium development; leveraged to uranium spot price; long lead times to production, requires significant financing.
0 · Reply
PaytiencePaysGreen
PaytiencePaysGreen Feb. 9 at 11:35 PM
$RGNX yet another AA potential suddenly become longer duration than normal. Same for qure. How about $LRMR price is depressed because of this potential, maybe?
1 · Reply
tonkotsu
tonkotsu Feb. 9 at 7:20 AM
$LRMR Took a deep look at this company after someone made a big option call. I’m not shorting this but I don’t think this medication will be that good. 1) Anaphylaxis risk in patients with heart issues from FA likely has a higher risk of death. 2) This medication mostly likely doesn’t cross brain barrier. They have definitely done mice models and tested brain samples, but didn’t report it because it has no effect on brain/CNS. Can help quality of life and prolong life a little bit but likely not much beyond that.
1 · Reply
Guerreraa
Guerreraa Feb. 8 at 7:49 PM
$LRMR reported $200M+ in cash and equivalents, giving it runway through late‑2026, which should fund core clinical and regulatory activities without immediate dilution…
0 · Reply
Guerreraa
Guerreraa Feb. 8 at 7:47 PM
$LRMR
0 · Reply
DrMerpMcMerpleton
DrMerpMcMerpleton Feb. 7 at 12:35 PM
$LRMR looks like someone bought $500K of April $5 calls. I’ve seen this type of action before, maybe this time there is good news.
0 · Reply
Aawilliam2003
Aawilliam2003 Feb. 4 at 5:43 PM
$LRMR this is not trading well. Who thinks they will get the nod to file in Q2? There are several other companies making waves in this space that may complicate their efforts eg $LXEO $SLDB
2 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 29 at 2:24 AM
$LRMR RSI: 59.70, MACD: -0.0193 Vol: 0.21, MA20: 3.45, MA50: 3.59 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
mmtiddy
mmtiddy Jan. 28 at 12:22 PM
$LRMR Nice steady gain last purchase, looking hard for next month
0 · Reply
Bigeyes2
Bigeyes2 Jan. 25 at 8:54 PM
$LRMR waiting for it to break the trend line, gap to fill
0 · Reply
Buss
Buss Jan. 24 at 2:26 AM
$LRMR Nice absorption and assimilation of that 320K market order block that punched thru @ 10:51 this morning. Somebody wanted out, got out, temporarily stunned the bullish intraday upside momentum, and that one minute downward spike was fully engulfed and closed above by day's end. This remains a good sign for the overall bullish bias at these absurdly low levels that seems to be the prevailing sentiment, as all 3 MA's were decisively closed above in conjunction with a nice daily volume surge as well. Happy weekend all. Be Blessed traders! :)
0 · Reply